Cargando…

Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country

BACKGROUND: This study was conducted to evaluate the microbiological profile of bacterial isolates in febrile neutropenia in a pediatric oncology unit, thereby, reviewing the use of restricted antibiotics and need for aggressive medical treatment accordingly. METHODS: A prospective observational stu...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Vinson, Prakash, Anand, Mehta, Kayur, Durugappa, Tarangini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214767/
https://www.ncbi.nlm.nih.gov/pubmed/34147094
http://dx.doi.org/10.1186/s13027-021-00387-y
_version_ 1783710120746680320
author James, Vinson
Prakash, Anand
Mehta, Kayur
Durugappa, Tarangini
author_facet James, Vinson
Prakash, Anand
Mehta, Kayur
Durugappa, Tarangini
author_sort James, Vinson
collection PubMed
description BACKGROUND: This study was conducted to evaluate the microbiological profile of bacterial isolates in febrile neutropenia in a pediatric oncology unit, thereby, reviewing the use of restricted antibiotics and need for aggressive medical treatment accordingly. METHODS: A prospective observational study was conducted in a paediatric haemat-oncology division of a tertiary care teaching hospital in southern India from September 2014 to August 2016. One hundred and thirty children with febrile neutropenia were enrolled in the study. Blood cultures were performed using automated system. Cultures from other sites were obtained if needed, based on the clinical profile. Standard antibiotic susceptibility testing was done. Statistical analysis was done using SPSS. RESULTS: One hundred and thirty children were enrolled for the study. Two hundred and fifty episodes of febrile neutropenia were studied. Three hundred and eighty four cultures were sent and 92 (24%) cultures were positive. There were 48 (52.2%) Gram negative isolates followed by 33 (35.8%) Gram positive isolates, six (6.5%) fungal isolates and five (5.5%) poly-microbial cultures. Lactose fermenting Gram negative bacilli (20 isolates, 31.5%) were the most frequently isolated in the Gram negative group, with Escherichia coli being the most common organism (19 isolates, 20.6%). Amongst the Gram positive coagulase negative staphylococcus was the most common (twenty seven isolates, 29%). Escherichia coli and Non lactose fermenting gram negative bacteria (NFGNB) had only 36, 25% sensitivity to ceftazidime, respectively. Most Gram negative bacilli were found to have better sensitivity to amikacin (mean: 57%). There was a higher prevalence of extended spectrum beta lactamase producing organisms. Pan drug resistance, Extreme drug resistance and Multi drug resistance was found in three, twenty and thirteen Gram negative isolates respectively.Escherichia coli and Klebsiella were often drug resistant. Significantly higher mortality was associated with Gram negative isolates (eight deaths out of the thirteen deaths, 61.5%). CONCLUSIONS: Our results show the importance of surveillance, monitoring resistance frequencies and identifying risk factors specific to each region. Given that significant mortality is attributed to drug resistant Gram negative bacilli, early initiation of appropriate antibiotics to cover for drug resistance is required while formulating empirical antibiotic policies for febrile neutropenia in the oncology units in the developing world.
format Online
Article
Text
id pubmed-8214767
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82147672021-06-23 Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country James, Vinson Prakash, Anand Mehta, Kayur Durugappa, Tarangini Infect Agent Cancer Research Article BACKGROUND: This study was conducted to evaluate the microbiological profile of bacterial isolates in febrile neutropenia in a pediatric oncology unit, thereby, reviewing the use of restricted antibiotics and need for aggressive medical treatment accordingly. METHODS: A prospective observational study was conducted in a paediatric haemat-oncology division of a tertiary care teaching hospital in southern India from September 2014 to August 2016. One hundred and thirty children with febrile neutropenia were enrolled in the study. Blood cultures were performed using automated system. Cultures from other sites were obtained if needed, based on the clinical profile. Standard antibiotic susceptibility testing was done. Statistical analysis was done using SPSS. RESULTS: One hundred and thirty children were enrolled for the study. Two hundred and fifty episodes of febrile neutropenia were studied. Three hundred and eighty four cultures were sent and 92 (24%) cultures were positive. There were 48 (52.2%) Gram negative isolates followed by 33 (35.8%) Gram positive isolates, six (6.5%) fungal isolates and five (5.5%) poly-microbial cultures. Lactose fermenting Gram negative bacilli (20 isolates, 31.5%) were the most frequently isolated in the Gram negative group, with Escherichia coli being the most common organism (19 isolates, 20.6%). Amongst the Gram positive coagulase negative staphylococcus was the most common (twenty seven isolates, 29%). Escherichia coli and Non lactose fermenting gram negative bacteria (NFGNB) had only 36, 25% sensitivity to ceftazidime, respectively. Most Gram negative bacilli were found to have better sensitivity to amikacin (mean: 57%). There was a higher prevalence of extended spectrum beta lactamase producing organisms. Pan drug resistance, Extreme drug resistance and Multi drug resistance was found in three, twenty and thirteen Gram negative isolates respectively.Escherichia coli and Klebsiella were often drug resistant. Significantly higher mortality was associated with Gram negative isolates (eight deaths out of the thirteen deaths, 61.5%). CONCLUSIONS: Our results show the importance of surveillance, monitoring resistance frequencies and identifying risk factors specific to each region. Given that significant mortality is attributed to drug resistant Gram negative bacilli, early initiation of appropriate antibiotics to cover for drug resistance is required while formulating empirical antibiotic policies for febrile neutropenia in the oncology units in the developing world. BioMed Central 2021-06-19 /pmc/articles/PMC8214767/ /pubmed/34147094 http://dx.doi.org/10.1186/s13027-021-00387-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
James, Vinson
Prakash, Anand
Mehta, Kayur
Durugappa, Tarangini
Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country
title Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country
title_full Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country
title_fullStr Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country
title_full_unstemmed Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country
title_short Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country
title_sort re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214767/
https://www.ncbi.nlm.nih.gov/pubmed/34147094
http://dx.doi.org/10.1186/s13027-021-00387-y
work_keys_str_mv AT jamesvinson rethinkingtreatmentstrategiesforfebrileneutropeniainpaediatriconcologypopulationtheperspectivefromadevelopingcountry
AT prakashanand rethinkingtreatmentstrategiesforfebrileneutropeniainpaediatriconcologypopulationtheperspectivefromadevelopingcountry
AT mehtakayur rethinkingtreatmentstrategiesforfebrileneutropeniainpaediatriconcologypopulationtheperspectivefromadevelopingcountry
AT durugappatarangini rethinkingtreatmentstrategiesforfebrileneutropeniainpaediatriconcologypopulationtheperspectivefromadevelopingcountry